# A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Source: https://onco.cc/trials/nct07365995/  
OnCo record `nct07365995` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing BNT324 in prostate cancer, now recruiting.

## Summary

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer is a phase 3 interventional study registered as NCT07365995, led by BioNTech SE with BioNTech (Shanghai) Pharmaceuticals and DualityBio, and recruiting on the registry. Official title: A Phase III, Randomised, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer. Planned enrolment is 736 participants (estimated). The study started in 2026-04-22 and primary completion is expected in 2031-02. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07365995
- Phase: 3
- Setting: A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer
- Sponsor: BioNTech SE
- Enrolled: 736

## Sources

- ClinicalTrials.gov NCT07365995: https://clinicaltrials.gov/study/NCT07365995

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [BNT324](https://onco.cc/drugs/bnt324/)
- companies: [BioNTech](https://onco.cc/companies/biontech/)

---
JSON: https://onco.cc/api/v1/entities/nct07365995.json